Paris: Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. This acquisition strengthens Sanofi's ...

Sanofi completes the acquisition of Vigil Neuroscience, Inc.Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. ('Vigil”). This acquisition ...

Resting-state EEG (RS-EEG) has emerged as a non-invasive, low-cost tool for Alzheimer’s disease (AD) diagnosis and ...

Converging evidence supports a key pathogenic role of the glymphatic system in the accumulation of pathological aggregates in ...

The Spain-based CDMO strengthens its North American presence and capabilities through its purchase, while also acquiring a ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Foreign firms showed mixed reactions to the decision, with some willing to offload a 5% stake while others were not ...

The French pharmaceutical company claims that Sarclisa-VRD showed great improvement in the minimum residual disease (MRD) ...

U.S. sales of Eylea HD and Eylea, treatments for eye conditions like wet age-related macular degeneration, decreased 25% in ...

Arrowhead Pharmaceuticals strikes a $130M+ deal with Sanofi for plozasiran in Greater China, targeting high triglyceride ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

Q2 2025 Management View Paul Hudson, CEO, reported "another strong quarter with double-digit sales growth," attributing the ...